logo-loader
Advanced Oncotherapy PLC

Advanced Oncotherapy passes key technological milestone

Researchers at the CERN facility in Geneva working on the company’s LIGHT system have confirmed it is now generating proton beams with sufficient energy to treat superficial tumours

researchers at CERN
The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle'

Advanced Oncotherapy PLC (LON:AVO) said it has passed a key technological milestone on schedule.

Researchers at the CERN facility in Geneva working on the company’s LIGHT system have confirmed it is now generating proton beams with sufficient energy to treat superficial tumours.

“This announcement marks the shift from a complex ‑ albeit well-proven ‑ scientific and physics reality into a medical application with tangible and direct implications for patients,” said chief executive Nicolas Sérandour.

“This very important step supports the confidence we have in delivering our plan and being in a position to offer a system that delivers a better outcome for patients whilst generating more value for the operators."

The results from the work to date showed the LIGHT proton beam technology comfortably treated simulated superficial tumours and marginally deeper cancers.

Healthy tissue, such as the eye and the lens, was spared because of the targeted nature of the device. Dosing was well controlled.

Next target in sight 

The development team is now focused on the “relatively low-execution risk activity” of adding further accelerating modules.

This will ensure the AVO equipment can treat all indications suitable for proton therapy.

“A further technical update will be provided in the next few days,” the company said.

LIGHT stands for Linac Image Guided Hadron Technology. The AVO kit is cheaper and smaller than the current units, which are almost prohibitively expensive.

It has the ability to propel protons at the speeds generated by much larger machines.

The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle’.

Quick facts: Advanced Oncotherapy PLC

Price: £0.37

Market: LSE
Market Cap: £85.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17

2 min read